Early clinical experience with subcutaneous GR43175 in acute migraine: an overview

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Early clinical experience with subcutaneous GR43175 in acute migraine : an overview. / Tfelt-Hansen, P; Brand, J; Dano, P; Doenicke, A; Findley, L J; Iversen, Helle Klingenberg; Melchart, D; Sahlender, H M.

In: Cephalalgia : an international journal of headache, Vol. 9 Suppl 9, 1989, p. 73-7.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Tfelt-Hansen, P, Brand, J, Dano, P, Doenicke, A, Findley, LJ, Iversen, HK, Melchart, D & Sahlender, HM 1989, 'Early clinical experience with subcutaneous GR43175 in acute migraine: an overview', Cephalalgia : an international journal of headache, vol. 9 Suppl 9, pp. 73-7.

APA

Tfelt-Hansen, P., Brand, J., Dano, P., Doenicke, A., Findley, L. J., Iversen, H. K., Melchart, D., & Sahlender, H. M. (1989). Early clinical experience with subcutaneous GR43175 in acute migraine: an overview. Cephalalgia : an international journal of headache, 9 Suppl 9, 73-7.

Vancouver

Tfelt-Hansen P, Brand J, Dano P, Doenicke A, Findley LJ, Iversen HK et al. Early clinical experience with subcutaneous GR43175 in acute migraine: an overview. Cephalalgia : an international journal of headache. 1989;9 Suppl 9:73-7.

Author

Tfelt-Hansen, P ; Brand, J ; Dano, P ; Doenicke, A ; Findley, L J ; Iversen, Helle Klingenberg ; Melchart, D ; Sahlender, H M. / Early clinical experience with subcutaneous GR43175 in acute migraine : an overview. In: Cephalalgia : an international journal of headache. 1989 ; Vol. 9 Suppl 9. pp. 73-7.

Bibtex

@article{40df097b1802474fb5e1f4b9c48cfe46,
title = "Early clinical experience with subcutaneous GR43175 in acute migraine: an overview",
abstract = "In six European clinics 111 migraine patients were treated in a series of open dose-ranging studies with subcutaneous injections of 1 to 4 mg GR43175, a novel 5-HT 1-like receptor agonist. Response rates after 20-30 min were dose related and rose from 33% with 1 mg to 96% with 4 mg GR43175. Side effects were minor and transient. These promising results warrant confirmation in placebo-controlled double-blind trials. Migraine, treatment, 5-HT agonist, open studies.",
keywords = "Adolescent, Adult, Aged, Dose-Response Relationship, Drug, Female, Humans, Indoles, Injections, Subcutaneous, Male, Middle Aged, Migraine Disorders, Sulfonamides, Sumatriptan",
author = "P Tfelt-Hansen and J Brand and P Dano and A Doenicke and Findley, {L J} and Iversen, {Helle Klingenberg} and D Melchart and Sahlender, {H M}",
year = "1989",
language = "English",
volume = "9 Suppl 9",
pages = "73--7",
journal = "Cephalalgia",
issn = "0800-1952",
publisher = "SAGE Publications",

}

RIS

TY - JOUR

T1 - Early clinical experience with subcutaneous GR43175 in acute migraine

T2 - an overview

AU - Tfelt-Hansen, P

AU - Brand, J

AU - Dano, P

AU - Doenicke, A

AU - Findley, L J

AU - Iversen, Helle Klingenberg

AU - Melchart, D

AU - Sahlender, H M

PY - 1989

Y1 - 1989

N2 - In six European clinics 111 migraine patients were treated in a series of open dose-ranging studies with subcutaneous injections of 1 to 4 mg GR43175, a novel 5-HT 1-like receptor agonist. Response rates after 20-30 min were dose related and rose from 33% with 1 mg to 96% with 4 mg GR43175. Side effects were minor and transient. These promising results warrant confirmation in placebo-controlled double-blind trials. Migraine, treatment, 5-HT agonist, open studies.

AB - In six European clinics 111 migraine patients were treated in a series of open dose-ranging studies with subcutaneous injections of 1 to 4 mg GR43175, a novel 5-HT 1-like receptor agonist. Response rates after 20-30 min were dose related and rose from 33% with 1 mg to 96% with 4 mg GR43175. Side effects were minor and transient. These promising results warrant confirmation in placebo-controlled double-blind trials. Migraine, treatment, 5-HT agonist, open studies.

KW - Adolescent

KW - Adult

KW - Aged

KW - Dose-Response Relationship, Drug

KW - Female

KW - Humans

KW - Indoles

KW - Injections, Subcutaneous

KW - Male

KW - Middle Aged

KW - Migraine Disorders

KW - Sulfonamides

KW - Sumatriptan

M3 - Journal article

C2 - 2544287

VL - 9 Suppl 9

SP - 73

EP - 77

JO - Cephalalgia

JF - Cephalalgia

SN - 0800-1952

ER -

ID: 128984851